ZIMMER BIOMET HOLDINGS, INC.

Listed Company

ZBHCIK 0001136869NYSELarge AcceleratedOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$8.23B

Net Income

$705.10M

Total Assets

$23.09B

Equity

$12.70B

Shares Out

195.65M

Op. Cash Flow

$1.70B

Business

Zimmer Biomet Holdings, Inc. designs, manufactures and markets medical devices and technologies to treat disorders and injuries of bones, joints and supporting soft tissues. Its products include reconstructive implants, sports medicine, biologics, extremities and trauma devices, craniomaxillofacial and thoracic products, surgical solutions, bone cements, and digital/robotic systems such as ROSA and the ZBEdge platform. Operations are organized into product categories including Knees, Hips, S.E.T. and Technology & Data, Bone Cement and Surgical. It sells to surgeons, hospitals, surgery centers and distributors across the Americas, EMEA and Asia Pacific through direct, consignment and stocking channels.

Summary from filing dated 2025-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net Sales	8,232	7,679	7,394	6,940	6,827
Cost of products sold, excluding intangible asset amortization	2,494	2,191	2,084	2,020	1,960
Intangible asset amortization	666	592	562	527	530
Research and development	459	437	459	406	436
Selling, general and administrative	3,257	2,930	2,839	2,762	2,843
Restructuring and other cost reduction initiatives	181	219	152	192	126
Acquisition, integration, divestiture and related	77	24	22	11	3
Operating expenses	7,133	6,393	6,117	6,244	5,967
Operating Profit	1,098	1,286	1,278	696	860
Other income (expense), net	26	−31	−9	−128	12
Interest expense, net	−293	−218	−201	−165	−208
Earnings before income taxes	831	1,037	1,067	404	499
Provision for income taxes	126	131	42	112	54
Net Earnings	705	905	1,025	291	446
Less: Net (loss) earnings attributable to noncontrolling interest	−100,000	2	1	1	500,000
Net Earnings of Zimmer Biomet Holdings, Inc.	705	904	1,024	231	402
Basic (per share)	3.56	4.45	4.91	1.1	1.93
Diluted (per share)	3.55	4.43	4.88	1.1	1.91
Basic (shares)	198	203	209	210	209
Diluted (shares)	199	204	210	210	210

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-04-30
Cash and cash equivalents	592	526	416	376	—
Accounts receivable, less allowance for credit losses	1,704	1,481	1,442	1,382	—
Inventories	2,286	2,235	2,385	2,147	—
Prepaid expenses and other current assets	537	430	366	523	—
Total Current Assets	5,120	4,672	4,610	4,427	—
Property, plant and equipment, net	2,207	2,049	2,060	1,873	—
Goodwill	9,947	8,951	8,819	8,580	48
Intangible assets, net	4,717	4,598	4,856	5,064	—
Other assets	1,100	1,096	1,152	1,122	—
Total Assets	23,092	21,365	21,497	21,066	—
Accounts payable	303	195	411	354	—
Other current liabilities	1,694	1,393	1,547	1,421	—
Current portion of long-term debt	587	863	900	544	—
Total Current Liabilities	2,584	2,451	2,857	2,358	—
Deferred income taxes, net	244	353	358	475	—
Other long-term liabilities	626	744	926	633	—
Long-term debt	6,932	5,342	4,868	5,152	—
Total Liabilities	10,386	8,889	9,009	9,039	—
Commitments and Contingencies (Note 20)	—	—	—	—	—
Common stock, $0.01 par value, one billion shares authorized, 318.7 million (317.5 million in 2024) issued	3	3	3	3	—
Paid-in capital	10,179	10,038	9,846	9,504	—
Retained earnings	11,611	11,095	10,385	9,559	—
Accumulated other comprehensive loss	−206	−263	−191	−179	—
Treasury stock, 123.2 million shares (118.4 million shares in 2024)	−8,889	−8,406	−7,562	−6,867	—
Total Zimmer Biomet Holdings, Inc. stockholders' equity	12,698	12,468	12,481	12,020	—
Noncontrolling interest	8	8	8	7	—
Total Stockholders' Equity	12,706	12,476	12,488	12,027	—
Total Liabilities and Stockholders' Equity	23,092	21,365	21,497	21,066	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	1,094	996	952	926	938
Share-based compensation	90	101	100	105	76
Deferred income tax benefit	−87	−48	−96	−64	−102
Income taxes	−167	−159	−74	−153	−124
Receivables	−127	−90	−52	−185	−41
Inventories	98	50	−240	−76	−8
Accounts payable and accrued liabilities	102	−322	−55	103	87
Other assets and liabilities	−11	65	23	−1	−48
Net cash provided by operating activities	1,697	1,499	1,582	—	1,499
Additions to instruments	−301	−240	−312	−258	−274
Additions to other property, plant and equipment	−225	−204	−291	−188	−144
Net investment hedge settlements	−400,000	22	33	89	2
Acquisition of intangible assets	−52	−153	−103	−30	−8
Business combination investments, net of acquired cash	−1,393	−276	−135	−100	—
Other investing activities	−5	−37	29	−36	−20
Net cash used in investing activities	−1,976	−888	−779	—	−504
Net payments on revolving facilities	—	−50	−325	−220	—
Proceeds from senior notes	2,492	1,436	500	—	1,600
Redemption of senior notes	−1,463	−850	−86	−1,276	−2,655
Payments on term loans	—	0	−34	−243	—
Dividends paid to stockholders	−190	−196	−201	−201	−200
Proceeds from employee stock compensation plans	40	82	101	78	123
Business combination contingent consideration payments	−25	−4	−10	—	−9
Debt issuance costs	−23	−13	−6	−2	−13
Repurchase of common stock	−487	−868	−692	−126	—
Other financing activities	−18	−22	−10	−5	−6
Net cash provided by (used in) financing activities	326	−485	−764	—	−1,306
Effect of exchange rates on cash and cash equivalents	19	−17	900,000	−15	−13
Increase in cash and cash equivalents	66	110	40	−103	−324

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro